Content area
Full Text
[Image omitted] - (http://www.fiercebiotech.com/story/psioxus-bags-39m-woodford-gsk-checkpoint-inhibitor-combo-trial/2015-05-19)
Neil Woodford
Neil Woodford 's new $1.2 billion fund and GlaxoSmithKline's ($GSK) VC unit have contributed to a $39 million Series C round in PsiOxus Therapeutics . The cash will allow PsiOxus to test its oncolytic virus together with a checkpoint inhibitor, a combination it thinks can make the immuno-oncology treatment effective against otherwise resistant targets.
Oxford, United Kingdom-based PsiOxus struck upon the idea after gathering data from another Phase I trial. The study showed an intravenous infusion of PsiOxus' lead product--the oncolytic virus enadenotucirev--selectively infects tumor cells. Once the tumor is infected, T cells are able to invade....